Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS P… (NCT04922814) | Clinical Trial Compass
CompletedNot Applicable
Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19
Egypt40 participantsStarted 2021-08-01
Plain-language summary
Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid patients, to participate in understanding of real hidden pathophysiology of COVID-19.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Severe ARDS: PaO2/FiO2 \<200, resistant hypoxemia and tachypnoea (RR \> 40 breath/minute)
* Not relieved by high frequency nasal canula or CPAP.
* Need for invasive mechanical ventilation (uncooperative)
Exclusion Criteria:
* Patient relatives' refusal
* Not mechanically ventilated.
* Combination of female, corticosteroids administration and vecuronium muscle relaxant.
* Neuromuscular diseases (especially demyelinating diseases).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial compared neuromuscular blocking agents — drugs that temporarily paralyze muscles — against sedation alone for severe COVID-19 ARDS; can you explain what the difference between these two approaches would mean for someone in my situation, and which one is currently considered standard care?
2The trial measured PaO2/FiO2 ratio as its main outcome, which tracks how well the lungs are passing oxygen into the blood — based on what this study found, did it show a meaningful improvement in lung function with the paralytic approach compared to sedation alone?
3Since this trial specifically listed ICU-acquired weakness as one of its conditions of interest, how does using neuromuscular blocking agents affect the risk of long-term muscle weakness, and is that a tradeoff worth discussing for my care plan?
4This trial is now completed but listed as Phase NA, meaning it may have been more of an observational or comparative study rather than a traditional drug trial — does that affect how much weight you'd give its findings when deciding on my treatment?
5Given that this trial focused on severe ARDS patients in the ICU, how would you determine whether the treatment approach studied here would be appropriate for where I currently am in my illness?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.